EDITORIALS

Biologic Risk Stratification of Medulloblastoma: The Real Time Is Now

Paul Graham Fisher, Peter C. Burger, and Charles G. Eberhart

JCO Mar 15 2004: 971–974. First published on Feb 17 2004; 10.1200/JCO.2004.12.939. [Full Text] [PDF]

p53 and RB: Simple Interesting Correlates or Tumor Markers of Critical Predictive Nature?

Carlos Cordon-Cardo

JCO Mar 15 2004: 975–977. First published on Feb 23 2004; 10.1200/JCO.2004.12.994. [Full Text] [PDF]

Prophylactic Oophorectomy and Hormone Replacement Therapy: Protection at What Price?

Judy Ellen Garber and Anne-Renee Hartman

JCO Mar 15 2004: 978–980. First published on Feb 23 2004; 10.1200/JCO.2004.01.926. [Full Text] [PDF]

Prophylactic Mastectomy for BRCA1/2 Carriers: Progress and More Questions

Lynn C. Hartmann, Amy Degnim, and Daniel J. Schaid

JCO Mar 15 2004: 981–983. First published on Feb 23 2004; 10.1200/JCO.2004.01.925. [Full Text] [PDF]

ORIGINAL REPORTS
Pediatric Oncology
	Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for Medulloblastoma
	Amar Gajjar, Roberto Hernan, Mehmet Kocak, Christine Fuller, Youngsoo Lee, Peter J. McKinnon, Dana Wallace, Ching Lau, Murali Chintagumpala, David M. Ashley, Stewart J. Kellie, Larry Kun, and Richard J. Gilbertson
	JCO Mar 15 2004: 984–993. First published on Feb 17 2004; 10.1200/JCO.2004.06.032. [Abstract] [Full Text] [PDF]
	Combining Gene Expression Profiles and Clinical Parameters for Risk Stratification in Medulloblastomas
	Ana Fernandez-Teijeiro, Rebecca A. Betensky, Lisa M. Sturla, John Y.H. Kim, Pablo Tamayo, and Scott L. Pomeroy
	JCO Mar 15 2004: 994–998. First published on Feb 17 2004; 10.1200/JCO.2004.03.036. [Abstract] [Full Text] [PDF]
	Psychological Outcomes in Long-Term Survivors of Childhood Brain Cancer: A Report From the Childhood Cancer Survivor Study
	Brad J. Zebrack, James G. Gurney, Kevin Oeffinger, John Whitton, Roger J. Packer, Ann Mertens, Norman Turk, Robert Castleberry, ZoAnn Dreyer, Leslie L. Robison, and Lonnie K. Zeltzer
	JCO Mar 15 2004: 999–1006. [Abstract] [Full Text] [PDF]

Genitourinary Cancer
	Combined Effects of p53, p21, and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma
	Sunanda J. Chatterjee, Ram Datar, David Youssefzadeh, Ben George, Peter J. Goebell, John P. Stein, Lillian Young, Shan-Rong Shi, Conway Gee, Susan Groshen, Donald G. Skinner, and Richard J. Cote
	JCO Mar 15 2004: 1007–1013. First published on Feb 23 2004; 10.1200/JCO.2004.05.174. [Abstract] [Full Text] [PDF]
	p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer
	Shahrokh F. Shariat, Hideo Tokunaga, JainHua Zhou, JaHong Kim, Gustavo E. Ayala, William F. Benedict, and Seth P. Lerner
	JCO Mar 15 2004: 1014–1024. First published on Feb 23 2004; 10.1200/JCO.2004.03.118. [Abstract] [Full Text] [PDF]
	Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)
	Eric J. Small, Susan Halabi, Nancy A. Dawson, Walter M. Stadler, Brian I. Rini, Joel Picus, Preston Gable, Frank M. Torti, Ellen Kaplan, and Nicholas J. Vogelzang
	JCO Mar 15 2004: 1025–1033. [Abstract] [Full Text] [PDF]
	2-18fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial
	Maria De Santis, Alexander Becherer, Carsten Bokemeyer, Franz Stoiber, Karin Oechsle, Franz Sellner, Alois Lang, Kurt Kletter, Bernhard M. Dohmen, Christian Dittrich, and Jörg Pont
	JCO Mar 15 2004: 1034–1039. [Abstract] [Full Text] [PDF]

Gynecologic Cancer
	Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment
	Viviane Hess, Roger A'Hern, Nazar Nasiri, D. Michael King, Peter R. Blake, Desmond P.J. Barton, John H. Shepherd, T. Ind, J. Bridges, K. Harrington, Stanley B. Kaye, and Martin E. Gore
	JCO Mar 15 2004: 1040–1044. [Abstract] [Full Text] [PDF]

Breast Cancer
	Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis
	Katrina Armstrong, J. Sanford Schwartz, Thomas Randall, Stephen C. Rubin, and Barbara Weber
	JCO Mar 15 2004: 1045–1054. First published on Feb 23 2004; 10.1200/JCO.2004.06.090. [Abstract] [Full Text] [PDF]
	Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
	Timothy R. Rebbeck, Tara Friebel, Henry T. Lynch, Susan L. Neuhausen, Laura van ’t Veer, Judy E. Garber, Gareth R. Evans, Steven A. Narod, Claudine Isaacs, Ellen Matloff, Mary B. Daly, Olufunmilayo I. Olopade, and Barbara L. Weber
	JCO Mar 15 2004: 1055–1062. First published on Feb 23 2004; 10.1200/JCO.2004.04.188. [Abstract] [Full Text] [PDF]
	Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
	Debu Tripathy, Dennis J. Slamon, Melody Cobleigh, Andrew Arnold, Mansoor Saleh, Joanne E. Mortimer, Maureen Murphy, and Stanford J. Stewart
	JCO Mar 15 2004: 1063–1070. [Abstract] [Full Text] [PDF]
	Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization–Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial
	K.L. Tedesco, A.D. Thor, D.H. Johnson, Y. Shyr, K.A. Blum, L.J. Goldstein, W.J. Gradishar, B.P. Nicholson, D.E. Merkel, D. Murrey, S. Edgerton, and G.W. Sledge, Jr
	JCO Mar 15 2004: 1071–1077. [Abstract] [Full Text] [PDF]

Hematologic Malignancies
	Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)
	Peter L. Greenberg, Sandra J. Lee, Ranjana Advani, Martin S. Tallman, Branimir I. Sikic, Louis Letendre, Kathleen Dugan, Bert Lum, David L. Chin, Gordon Dewald, Elisabeth Paietta, John M. Bennett, and Jacob M. Rowe
	JCO Mar 15 2004: 1078–1086. [Abstract] [Full Text] [PDF]
	Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461
	John C. Byrd, Amy S. Ruppert, Krzysztof Mrózek, Andrew J. Carroll, Colin G. Edwards, Diane C. Arthur, Mark J. Pettenati, Judith Stamberg, Prasad R.K. Koduru, Joseph O. Moore, Robert J. Mayer, Frederick R. Davey, Richard A. Larson, and Clara D. Bloomfield
	JCO Mar 15 2004: 1087–1094. [Abstract] [Full Text] [PDF]
	Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
	Steven M. Devine, Neal Flomenberg, David H. Vesole, Jane Liesveld, Daniel Weisdorf, Karin Badel, Gary Calandra, and John F. DiPersio
	JCO Mar 15 2004: 1095–1102. [Abstract] [Full Text] [PDF]

Lung Cancer
	Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
	Vincent A. Miller, Mark G. Kris, Neelam Shah, Jyoti Patel, Christopher Azzoli, Jorge Gomez, Lee M. Krug, William Pao, Naiyer Rizvi, Barbara Pizzo, Leslie Tyson, Ennapadam Venkatraman, Leah Ben-Porat, Natalie Memoli, Maureen Zakowski, Valerie Rusch, and Robert T. Heelan
	JCO Mar 15 2004: 1103–1109. [Abstract] [Full Text] [PDF]
	Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer
	Charles M. Rudin, Mark Kozloff, Philip C. Hoffman, Martin J. Edelman, Robyn Karnauskas, Ronald Tomek, Livia Szeto, and Everett E. Vokes
	JCO Mar 15 2004: 1110–1117. [Abstract] [Full Text] [PDF]

Melanoma
	Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study
	M.F. Avril, S. Aamdal, J.J. Grob, A. Hauschild, P. Mohr, J.J. Bonerandi, M. Weichenthal, K. Neuber, T. Bieber, K. Gilde, V. Guillem Porta, J. Fra, J. Bonneterre, P. Saïag, D. Kamanabrou, H. Pehamberger, J. Sufliarsky, J.L. Gonzalez Larriba, A. Scherrer, and Y. Menu
	JCO Mar 15 2004: 1118–1125. [Abstract] [Full Text] [PDF]

REVIEW ARTICLE
	Evaluation of Diagnostic Assessment Units in Oncology: A Systematic Review
	Anna Gagliardi, Eva Grunfeld, and William K. Evans
	JCO Mar 15 2004: 1126–1135. [Abstract] [Full Text] [PDF]

BIOLOGY OF NEOPLASIA
	Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
	Markus Y. Mapara and Megan Sykes
	JCO Mar 15 2004: 1136–1151. [Abstract] [Full Text] [PDF]

DIAGNOSIS IN ONCOLOGY

Unusual Sites of Metastatic Involvement: CASE 1. Right Ventricular Outflow Obstruction Caused by Metastatic Hepatocellular Carcinoma

Tzu Yu Lin, Kuan Ming Chiu, Chen Yen Chien, Ming Jiuh Wang, and Shu Hsun Chu

JCO Mar 15 2004: 1152–1153. [Full Text] [PDF]

Unusual Sites of Metastatic Involvement: CASE 2. Intracardiac Metastasis From a Merkel Cell Carcinoma

M.R.M. Jongbloed, B.L.J. Kanen, M. Visser, H. Niessen, M.J. Flens, and R.J.L.F. Loffeld

JCO Mar 15 2004: 1153–1156. [Full Text] [PDF]

Unusual Sites of Metastatic Involvement: CASE 3. Grey-Turner's Sign As the First Indication of a Ruptured Hepatocellular Carcinoma

V.A. Sevastianos, M. Deutsch, and S.P. Dourakis

JCO Mar 15 2004: 1156–1157. [Full Text] [PDF]

SPECIAL DEPARTMENTS

Correspondence

Ototoxicity in Patients With Dose-Intensive Therapy for Cisplatin-Resistant Germ Cell Tumors

Adrian Dubs, Emanuel Jacky, Rolf Stahel, Christian Taverna, and Hanspeter Honegger

JCO Mar 15 2004: 1158. [Full Text] [PDF]

In Reply:

Robert J. Motzer

JCO Mar 15 2004: 1158-a–1159. [Full Text] [PDF]

High-Risk Lesions in High-Risk Women: A High-Risk Formalin-Based Biology!

Camilo Adem, Robert B. Jenkins, Frédérique Capron, and Dominique Stoppa-Lyonnet

JCO Mar 15 2004: 1159–1161. [Full Text] [PDF]

In Reply:

Nicoline Hoogerbrugge, Peter Bult, and Han Brunner

JCO Mar 15 2004: 1161–1162. [Full Text] [PDF]

Doomed Trials for Promising Adenoviruses: A Rationale for Success

Enrique Casado, Javier De Castro, Cristóbal Belda-Iniesta, Jaime Feliu, Manuel González-Barón, and Waleed Arafat

JCO Mar 15 2004: 1162–1163. [Full Text] [PDF]

In Reply:

Lance C. Pagliaro

JCO Mar 15 2004: 1163–1164. [Full Text] [PDF]

Hormonal Treatment Duration in Elderly Patients: An Open Question

Diana Crivellari, Aron Goldhirsch, and Alan Coates

JCO Mar 15 2004: 1164–1165. [Full Text] [PDF]

In Reply:

Antonio Nicolucci, Maurizio Belfiglio, Fabio Pellegrini, Michele Sacco, and Miriam Valentini

JCO Mar 15 2004: 1165. [Full Text] [PDF]

Is Withdrawal of Consolidation Radiotherapy an Evidence-Based Strategy in Primary Central Nervous System Lymphomas?

Michele Reni and Andrés J.M. Ferreri

JCO Mar 15 2004: 1165-a–1167. [Full Text] [PDF]

In Reply:

K. Hoang-Xuan and J.Y. Delattre

JCO Mar 15 2004: 1167–1168. [Full Text] [PDF]

Erratum

ERRATUM

JCO Mar 15 2004: 1169. [Full Text] [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.